Lyell Immunopharma Inc (LYEL) Stock Price, Quote & News

Company Profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 695 0677

Website: www.lyell.com

Address:

201 Haskins Way, South San Francisco, United States

Ron13699 Mar. 11 at 2:16 PM

$LYEL Shit

1 · Reply

BillionerOfKing Mar. 10 at 5:32 PM

$LYEL Current Stock Price: $26.43 Contracts to trade: $26.0 LYEL Mar 20 2026 Call Entry: $0.10 Exit: $0.13 ROI: 25% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

svb64 Mar. 9 at 9:53 PM

$LYEL news?

0 · Reply

Mdugs Mar. 9 at 4:47 PM

$LYEL hurray

0 · Reply

terra987 Mar. 3 at 1:35 PM

$LYEL Uptrend

0 · Reply

thetaowen Feb. 20 at 3:59 PM

$LYEL Lyell Immunopharma develops T-cell therapies. Clinical execution drives valuation. Development risk remains high.

0 · Reply

MaryThomas194 Feb. 18 at 12:42 PM

$LYEL Cell therapy biotech with platform potential; cash runway defines risk profile.

0 · Reply

Mdugs Feb. 17 at 5:19 PM

$LYEL hmm?

1 · Reply

OfficialStocktwitsUser Feb. 13 at 6:15 PM

$LYEL RSI: 57.84, MACD: -0.4098 Vol: 1.07, MA20: 24.47, MA50: 27.59 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

TheTradeXchange Feb. 12 at 12:31 PM

$LYEL - Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma

0 · Reply

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Mar 9, 2026, 8:00 AM EDT - 6 days ago

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Mar 6, 2026, 4:55 PM EST - 9 days ago

Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Feb 23, 2026, 8:00 AM EST - 20 days ago

Lyell Immunopharma Announces Participation in March Investor Conferences

Feb 12, 2026, 7:30 AM EST - 4 weeks ago

Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma

Dec 24, 2025, 8:30 AM EST - 2 months ago

Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data

Dec 7, 2025, 4:30 PM EST - 3 months ago

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Nov 12, 2025, 4:05 PM EST - 4 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025

Nov 10, 2025, 7:30 AM EST - 4 months ago

Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

Nov 3, 2025, 9:00 AM EST - 4 months ago

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Sep 3, 2025, 8:00 AM EDT - 6 months ago

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

Sep 2, 2025, 4:05 PM EDT - 6 months ago

Lyell Immunopharma Announces Participation in September Investor Conferences

Aug 12, 2025, 4:05 PM EDT - 7 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

Jul 25, 2025, 8:00 AM EDT - 8 months ago

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

Jul 22, 2025, 9:02 AM EDT - 8 months ago

Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement

Jun 23, 2025, 5:00 PM EDT - 9 months ago

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

Jun 17, 2025, 6:30 AM EDT - 9 months ago

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

Jun 9, 2025, 4:05 PM EDT - 9 months ago

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

Jun 4, 2025, 4:05 PM EDT - 10 months ago

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

May 13, 2025, 4:05 PM EDT - 10 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

May 1, 2025, 9:00 AM EDT - 11 months ago

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

$Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma$

Apr 15, 2025, 9:00 AM EDT - 11 months ago

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Mar 11, 2025, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Feb 18, 2025, 4:05 PM EST - 1 year ago

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Jan 9, 2025, 9:00 AM EST - 1 year ago

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Dec 9, 2024, 9:00 PM EST - 1 year ago

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Nov 5, 2024, 9:30 AM EST - 1 year ago

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Oct 31, 2024, 4:00 PM EDT - 1 year ago

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Oct 25, 2024, 9:24 AM EDT - 1 year ago

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Oct 24, 2024, 4:00 PM EDT - 1 year ago

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 24, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

Jun 26, 2024, 7:00 AM EDT - 1 year ago

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

May 7, 2024, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

May 6, 2024, 8:00 AM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

Apr 16, 2024, 6:25 PM EDT - 2 years ago

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Mar 5, 2024, 4:30 PM EST - 2 years ago

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

Feb 28, 2024, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Jan 3, 2024, 4:05 PM EST - 2 years ago

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Nov 10, 2023, 2:23 PM EST - 2 years ago

Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL

Nov 9, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

Nov 7, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

Aug 31, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in Upcoming Investor Conferences

Aug 26, 2023, 9:29 AM EDT - 2 years ago

Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Jul 5, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

May 4, 2023, 4:05 PM EDT - 3 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

Ron13699 Mar. 11 at 2:16 PM

$LYEL Shit

1 · Reply

BillionerOfKing Mar. 10 at 5:32 PM

0 · Reply

svb64 Mar. 9 at 9:53 PM

$LYEL news?

0 · Reply

Mdugs Mar. 9 at 4:47 PM

$LYEL hurray

0 · Reply

terra987 Mar. 3 at 1:35 PM

$LYEL Uptrend

0 · Reply

thetaowen Feb. 20 at 3:59 PM

$LYEL Lyell Immunopharma develops T-cell therapies. Clinical execution drives valuation. Development risk remains high.

0 · Reply

MaryThomas194 Feb. 18 at 12:42 PM

$LYEL Cell therapy biotech with platform potential; cash runway defines risk profile.

0 · Reply

Mdugs Feb. 17 at 5:19 PM

$LYEL hmm?

1 · Reply

OfficialStocktwitsUser Feb. 13 at 6:15 PM

0 · Reply

TheTradeXchange Feb. 12 at 12:31 PM

$LYEL - Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma

0 · Reply

Mdugs Feb. 10 at 7:19 PM

$LYEL back in at 22.5 will average down lower but holding strong and I am riding til the end from here. Almost doubled my shares from the last run so I’m happy. GL

0 · Reply

OfficialStocktwitsUser Feb. 5 at 11:19 PM

$LYEL RSI: 48.79, MACD: -0.8738 Vol: 0.86, MA20: 24.30, MA50: 27.39 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

NVDAMillionaire Feb. 4 at 5:29 PM

$LYEL Great piece that accurately captures LYEL's current position. So if you want to refresh your understanding of LYEL or learn about LYEL for the first time, this is essential reading. https://everyticker.com/quote/LYEL/analysis/lyell-immunopharma-s-manufacturing-edge-meets-clinical-trial-risk-nasdaq-lyel

0 · Reply

PortfolioPrince Feb. 4 at 4:06 PM

$LYEL is a clinical-stage biotech (Lyell Immunopharma) developing cell therapies for cancer; its pipeline is early-stage and utilizes novel but unproven technologies to overcome cell therapy resistance.

0 · Reply

50bps Jan. 22 at 3:55 PM

$LYEL 👀

0 · Reply

Mdugs Jan. 22 at 3:26 PM

$LYEL oof. Hoping it comes back down it was bouncing around 23 for a few

0 · Reply

Peterson28 Jan. 2 at 4:52 PM

$LYEL MM exited their positions on the pump too. Back to 13ish for an re entry.

0 · Reply

medguy Dec. 30 at 10:17 PM

Looking for bounce $CORT $DGNX $THH $LYEL

0 · Reply

Mdugs Dec. 26 at 11:06 PM

$LYEL come back to papa

0 · Reply

ExcellenceExpert Dec. 26 at 12:35 PM

$LYEL Trading behavior shows investors weighing repeatability of results above expansion claims. Forecast discipline should become more precise and conservative. Evidence of repeatability is likely to change market tone. Durable value creation requires execution to catch up with vision.

1 · Reply

ZacksResearch Dec. 24 at 6:09 PM

Biotech momentum is BACK — and these names are already up big 👀🚀 $MLYS, $LYEL, $NKTR and $INSM are all up more than 50% in 2025, powered by clinical wins, FDA approvals, and M&A deals that are reviving confidence across the drug and biotech space heading into 2026. See why these high-flyers may still have room to grow 👉 https://www.zacks.com/stock/news/2808693/4-drug-biotech-stocks-rising-more-than-50-in-2025-with-room-to-grow?cid=sm-stocktwits-2-2808693-teaser-26257&ADID=SYND_STOCKTWITS_TWEET_2_2808693_TEASER_26257

0 · Reply

TalkMarkets Dec. 23 at 10:03 PM

#Goldman's Small-Cap #Biotech Universe: The 2026 Catalyst Playbook For Investors $ABCL $BIOA $ALLO $GOSS $LYEL https://talkmarkets.com/content/stocks--equities/goldmans-small-cap-biotech-universe-the-2026-catalyst-playbook-for-investors?post=546436

1 · Reply

Market Cap	451.44M
Revenue (ttm)	60,000.00
Net Income (ttm)	-342.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-571,650.00%
Debt to Equity Ratio	0.00

Volume	141,800
Avg Vol	107,804
Day's Range	N/A - N/A
Shares Out	21.24M
Stochastic %K	5%
Beta	-0.14
Analysts	Sell
Price Target	$30.75